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DOES COST-EFFECTIVENESS ANALYSIS DISCRIMINATE AGAINST PATIENTS
WITH SHORTER LIFE EXPECTANCY?
Paulden M, Culyer AJ
University of Toronto, Toronto, ON, Canada
OBJECTIVES: The UK’s National Institute for Health and Clinical Excellence (NICE)
has been accused of discriminating against patientswith shorter life expectancy by
embracing the use of quality-adjusted life years (QALYs) within cost-effectiveness
analysis (CEA). The basis of this claim is that patients with shorter life expectancy
have fewer QALYs to gain from treatment and so NICE’s guidance inherently dis-
criminates against such patients. Such criticisms may also be directed at similar
decision making agencies. Our objective was to formally identify the circum-
stances under which CEA-based decision-making discriminates on the basis of life
expectancy. METHODS: We developed a simple model of a CEA-based decision
making process in which a technology is considered cost-effective for a particular
patient cohort only if the ICER for that cohort lies below a fixed cost-effectiveness
threshold. For such decisionmaking to discriminate on the basis of life expectancy,
the ICERs for two hypothetical cohorts of patients – identical in all ways except life
expectancy – must lie on either side of the threshold. RESULTS:We find that CEA
does not inherently discriminate on the basis of life expectancy but that scope for
discrimination arises in the case of specific technologies having identifiable char-
acteristics. Such discrimination may in fact favour those patients with shorter life
expectancy. In all cases the use of discounting is shown to reduce the likelihood of
discrimination on the basis of life expectancy – this is particularly relevant in light
of the recent discussion around NICE’s discounting practices. CONCLUSIONS: It is
recommended that agencies such as NICE consider the possibility of discrimina-
tion arising from their use of CEA. Accusations of inherent discrimination, how-
ever, appear to be misplaced. It is argued that these claims are founded upon a
fundamentalmisunderstanding of the role of QALYs in CEA, particularlywithin the
decision rules adopted by policy makers.
QA4
IS THE AIM OF THE HEALTH CARE SYSTEM TO MAXIMISE QALYS? AN
INVESTIGATION OF ‘WHAT ELSE MATTERS’ IN THE NHS
Praet C1, Shah K2, Devlin N3, Sussex J2, Parkin D4, Appleby J5
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OBJECTIVES: It is often assumed that the objective of health care is solely to max-
imise health using available resources. This is the principle underpinning NICE’s
use of cost-effectiveness analysis based on incremental cost per QALY gained. Yet
research on local NHS decision-making shows that cost per QALY is far from the
only consideration. Similarly, many national NHS policy initiatives are driven pri-
marily not by QALY gain, but by ‘process-of-care’ and other considerations. The DH
is required to undertake and publish Impact Assessments (IAs) identifying the
costs and benefits expected fromall newpolicy implementation.We analyse all IAs
carried out in 2008-2009 to identify the benefits considered by the DH as relevant to
its decision making. METHODS: The stated benefits of each policy were extracted
from the relevant IA. A combination of methods was used to categorise these.
RESULTS: 51 IAs were analysed, 8 of whichmentioned QALY gains as a benefit. 162
benefits other than QALY gains were identified. Apart from improving health out-
comes, common types of benefit included reducing costs, improving quality of
care, and enhancing patient experience and empowerment. CONCLUSIONS:Many
of the policies reviewed were implemented on the basis of benefits unrelated to
health outcome. The methods being used to apply a monetary valuation to QALY
gains (in IA cost-benefit calculations) are not consistent across IAs, or with NICE’s
stated threshold range.We consider the implications for NHS decisionmaking and
NICE guidance, and the meaning of allocative efficiency in the NHS.
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USE OF STRUCTURAL EQUATION MODELING TO EXPLAIN CONSUMER
BEHAVIOR TOWARDS GENERIC DRUG DISCOUNT PROGRAMS
Patel HK, Sansgiry S
University of Houston, Houston, TX, USA
OBJECTIVES: The study attempts to assess the robustness of constructs with the
Theory of Planned Behavior (TPB) in explaining intention to use generic drug dis-
count programs (GDDPs). METHODS: A self-administered questionnaire was dis-
tributed to consumers filling a prescription at pharmacies in Houston (Texas, USA)
that offered GDDPs (CVS,Walgreens,Wal-Mart, Kroger, Target, Randalls, andH-E-B
stores). Constructs of TPB, namely, consumer’s attitude towards GDDPs, perceived
behavioral control (PBC), subjective norms (SN), and intention to use were mea-
sured using a pre-validated 5 point likert scale. The questionnaire also measured
consumer awareness regarding GDDPs, attitude towards generic drugs in general
alongwith demographic data. Structural equationmodeling (SEM) using AMOS v18
was used to test the proposed model. RESULTS: Response rate of 59.46% was ob-
tained (n  389). Scales developed to measure all the domains were reliable ( 
0.72-0.89). Majority (68.4%) of respondents were aware of GDDPs. Mean attitude
towards GDDPs (4.080.83) and intention to use (4.331.01) scores were high. The
SEM best fitmodel was the one where association of awareness with intention was
mediated by attitude towards GDDPs as there was no direct relationship (CMIN/df
3.29; p0.001; CFI0.904; RMSEA0.077). Further, attitude towards generics was
retained in the model and exerted a higher indirect effect on intention via attitude
towards GDDPs. The effect of PBC on intention was very low and SN was not
retained in the model. CONCLUSIONS: As pharmacy stores develop prescription
drug plans usingGDDPs to increase utilization and increase store loyalty, strategies
to improve consumer attitude towards generics and GDDPs will be useful. Contin-
uous information regarding these programs may increase awareness of such pro-
grams leading to a positive attitude and increased use.
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OBJECTIVES: To examine the trends in use and characteristics of patients using
discount generic prescription programs. METHODS: A cross-sectional survey of
patients in the University ofMichigan TaubmanGeneral Medicine Clinic was taken
over the course of two, four week intervals, first in the summer of 2008 and again in
2010. The survey was given in-person, in paper format, and was completed while
patients were waiting to see their physician. Self-reported information was gath-
ered on the patients’most recent prescriptionmedication use in two parts: a listing
of current medications (location of filling, price paid, brand/generic, discount pro-
gram use) and inquiries on program use, if applicable, as well as patient
demographics. RESULTS: The overall convenience sample over the two cohorts
included 414 individuals, 203 in 2008 and 211 in 2010. The sample was mostly
Caucasian (78.7%),most patients had prescription drug insurance coverage (92.1%),
and a large majority of medications filled were for chronic use (84.3%). Patient
demographics between the two populations were similar for all characteristics
with two exceptions: a higher mean number of medications was reported in 2010,
4.2 versus 3.4 (t  3.07, p0.01), and 29.9% of those surveyed in 2010 had used a
discount medication program versus 5.4% in 2008 (X2  42.10, p0.001). Factors
associated with program use included patient age 50 – 64 years (OR, 3.79; 95%
confidence interval [CI], 1.45 – 9.95; p0.004), an annual household income of less
than $24000 (OR, 2.64; CI, 1.12 – 6.22; p0.02), and the filling of medications for
chronic use (OR, 1.86; CI, 1.20 – 2.88; p0.005). CONCLUSIONS: Limited differences
in patientsmost likely to use discount prescriptionmedication programs existed in
the studied population. More extended analysis of such program utilization is
needed to better understand patient use of such services.
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OBJECTIVES: To expand on the scope of the limited prior research by reporting on
concluded investigations involving pharmaceuticalmanufacturers independent of
whether or not they involved qui tam relators between 1996-2010. METHODS: All
cases involved pharmaceutical manufacturers and FCA violations, which impose
liability of up to triple damages and civil penalties of $5,500 to $11,000 per claim for
submitting false claims to the government. Data were from Department of Justice
during 1996-2010. RESULTS: Since 1996, resolution of 31 FCA cases involving phar-
maceutical manufacturers accounted for $12 billion in recoveries. Total recoveries
were $8 million during 1996-2000 (one case), $3.9 billion during 2001-2005 (15
cases), and $8.1 billion during 2006- 2010 (15 cases). Billing fraud was implicated in
18 cases ($3.7 billion), off-label marketing in 12 cases ($4.4 billion), kick-backs in 5
cases ($1.7 billion), and producing defective pharmaceuticals in one case ($750
million).Qui tam relators initiated 77% of the cases (median reward $31million). Six
settlements included criminal fines. CONCLUSIONS: With expansion of govern-
ment healthcare, fraud investigations of pharmaceutical manufacturers will un-
doubtedly continue. These investigations have the potential to reduce costs and
improve the quality of pharmaceutical use.
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WHEN STAKEHOLDERS DON’T AGREE: DISCREPANCIES IN MAB “APPROVALS”
OVER THE PAST TEN YEARS
Miller KL, Stevens CA
PAREXEL Consulting, Waltham, MA, USA
OBJECTIVES: In the drug development process the priorities of the stakeholders
(manufacturers, payers, regulators, patients, physicians) often do not align, and at
times are in conflict, e.g. in the US consumers aren’t concerned about cost, but
private payers are.With cost as a significant driver tomultiple decisionmakers, we
explore monocolonal antibodies (mAb) as a drug class and the handling of their
approvals and authorizations by the US and UK key bodies.METHODS: The follow-
ing sources were summarized for mAbs approved in the past 10 years: the regula-
tory approval decision in the United States and the United Kingdom; the payer
coverage decision, if applicable and available; relevant patient advocacy groups’
statements; and statements on behalf of medical organizations. Discrepancies be-
tween initial regulatory decisions and the statements of the other stakeholders
were highlighted. RESULTS: These sources show the use of clinical data to advo-
cate differing stakeholders’ views. In the case of natalizumab, patient advocacy
groups and regulators disagreed on whether the risks outweighed the drug bene-
fits. In judging the value of bevacizumab for breast cancer patients, regulators and
payers are still at odds. Furthermore, the debate between the payers and the man-
ufacturer on the use of off-label bevacizumab seems to hinge on the clinical results
from the US National Eye Institute. CONCLUSIONS: Although physicians continue
to play a critical role in determining drug use once a product is approved, other
stakeholders (e.g. patients and independent researchers) are increasing their sway
A12 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 1 – A 2 1 4
